Hikma Agrees to Pay $50 Million to Settle Narcolepsy Drug Case

Hikma Pharmaceuticals Plc reached a $50 million deal to settle claims it colluded with other drugmakers to delay the generic version of brand-name narcolepsy drug Xyrem.

The proposed settlement, and the plaintiffs’ request for preliminary approval of the deal, was filed Wednesday in the US District Court for the Northern District of California. The deal with Hikma, the last defendant in the case, brings to $198.4 million the amount class plaintiffs have reached with defendants in the multidistrict litigation consolidated in 2020.

Jazz Pharmaceuticals Plc, which manufacturers Xyrem, said last month it would pay $145 million to settle the ...